B-Cell Lymphoblastic Lymphoma

Diseases /

B-Cell Lymphoblastic Lymphoma

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Fusion
ABL2
ABL2 Fusion
BCR
BCR-ABL1
BCR-ABL1 Fusion
CD19 Expression
CD22 Expression
CRLF2
CRLF2 Fusion
EPOR
EPOR Fusion
FGFR1
FGFR1 Fusion
FGFR2
FGFR2 Fusion
FGFR3
FGFR3 Fusion
FGFR4

FGFR4 Fusion
FLT3
FLT3 Fusion
IGH
IGH-MYC
IGH-MYC Fusion
IL7R
IL7R Mutation
JAK1
JAK1 Fusion

JAK1 Loss
JAK1 Mutation
JAK2
JAK2 Fusion
JAK2 Mutation
JAK3
JAK3 Fusion
JAK3 Mutation
LYN
LYN Fusion

MS4A1 Expression
MYC
NTRK1
NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3
NTRK3 Fusion
PDGFRA
PDGFRA Fusion

PDGFRB
PDGFRB Fusion
PTL2B fusion
SH2B3
SH2B3 Loss
SH2B3 Mutation
TYK2
TYK2 Fusion
Trisomy 21
t(8;14)(q24;q32)

t(9;22)(q34;q11)

Overview

NCI Definition: An uncommon type of lymphoma. It constitutes approximately 10% of cases of lymphoblastic lymphoma. Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age. The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes. It has a high remission rate with a median survival of approximately 60 months. (WHO, 2001) [1]

Clinical Trials

View Clinical Trials for B-Cell Lymphoblastic Lymphoma

There are 11 clinical trials for B-cell lymphoblastic lymphoma, of which 11 are open and 0 are completed or closed. Of the trials that contain B-cell lymphoblastic lymphoma as an inclusion criterion, 2 are early phase 1 (2 open), 2 are phase 1 (2 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).

CD22, BCR-ABL1, and CD19 are the most frequent gene inclusion criteria for B-cell lymphoblastic lymphoma clinical trials [3].

Trials Investigating B-Cell Lymphoblastic Lymphoma by Gene and Recruiting Status

Cyclophosphamide, vincristine, and cytarabine are the most common interventions in B-cell lymphoblastic lymphoma clinical trials.

Drugs Being Investigated in B-Cell Lymphoblastic Lymphoma Trials by Recruiting Status

Significant Genes in B-Cell Lymphoblastic Lymphoma

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

ABL2 +

ABL2 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CEP72 +

CEP72 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CEP72 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CRLF2 +

CRLF2 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CRLF2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

EPOR +

EPOR is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EPOR status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR4 +

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

IL7R +

IL7R is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IL7R status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK1 +

JAK1 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK1 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK2 +

JAK2 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK3 +

JAK3 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

LYN +

LYN is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains LYN status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK1 +

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK2 +

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK3 +

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

SH2B3 +

SH2B3 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SH2B3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

TYK2 +

TYK2 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TYK2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

Disease Details

Synonyms

Precur. B-lymphoblastic lymphoma, Precursor B-Lymphoblastic Lymphoma, Precursor B-lymphoblastic lymphoma, B-Lymphoblastic Lymphoma, B Lymphoblastic Lymphoma

Parent(s)

Lymphoblastic Lymphoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

B-Cell Lymphoblastic Lymphoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in B-Cell Lymphoblastic Lymphoma

Disease Details

References

About

Molecular Medicine

Content Types